retatrutide spray 5ML Nasal Do Retatrutide Drops + Nasal

Larger-scale federally licensed compounders (503B outsourcing facilities) have until March 19, 2025, to wind down their production and distribution of compounded tirzepatide

The STEP 1 trial (Wilding et al., The Lancet, 2021) showed an average weight loss of 14.9% over 68 weeks versus 2.4% in the placebo group a landmark result that established semaglutide as the benchmark for GLP-1 weight loss

Although the percentage of antidiabetes medication usage was higher in the placebo group, the difference was not statistically significant (p = 0.097)

After promising results, large-scale Phase III trials (the SUSTAIN program) were launched around 2015